View Older Stories View More Recent Stories

Aug 17, 2022 08:31AM Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Aug 16, 2022 06:59AM Bristol-Myers Squibb (BMY), Turning Point Therapeutics (TPRX) Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition
Aug 16, 2022 06:59AM Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Th
Aug 15, 2022 11:31AM Big Short's Burry Liquidates ~$200M in Long Stock Bets, Now Has Just One Stock
Aug 10, 2022 06:47AM Bristol-Myers Squibb (BMY) and 2seventy (TSVT) Report Positive Topline Results from KarMMa-3 Trial
Aug 10, 2022 06:45AM Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in
Aug 3, 2022 04:16PM Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
Jul 29, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports CheckMate -914 Trial Evaluating Opdivo Plus Yervoy Did Not Meet Endpoint
Jul 29, 2022 06:59AM Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
Jul 27, 2022 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
Jul 22, 2022 06:59AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab)
Jul 22, 2022 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Met
Jul 21, 2022 06:59AM Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow’s Innovators Program to Increase Black Representation in the Healthcare Industry
Jul 20, 2022 06:59AM Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities
Jul 19, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces Extension of Turning Point (TPTX) Tender Offer
Jul 19, 2022 06:59AM Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
Jun 27, 2022 06:04AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Jun 24, 2022 07:05PM U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Jun 24, 2022 12:52PM Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
Jun 24, 2022 12:51PM New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
Jun 20, 2022 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
Jun 15, 2022 04:16PM Bristol-Myers Squibb (BMY) Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
Jun 15, 2022 04:16PM Bristol Myers Squibb Announces Dividend
Jun 15, 2022 04:16PM Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
Jun 8, 2022 06:59AM Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022
Jun 7, 2022 06:59AM Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 6, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes
Jun 6, 2022 06:59AM Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Meta
Jun 6, 2022 06:59AM Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Met
Jun 3, 2022 05:01PM Bristol-Myers Squibb (BMY) Withdraws Supplemental BLA for Reblozyl for Non-transfusion Dependent (NTD) Beta Thalassemia
Jun 3, 2022 04:59PM Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
Jun 3, 2022 06:59AM Bristol-Myers Squibb (BMY) to Acquire Turning Point Therapeutics (TPTX) for $76 Per Share
Jun 3, 2022 06:59AM Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
Jun 2, 2022 11:02AM Bristol-Myers Squibb (BMY) Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
Jun 2, 2022 11:01AM Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
Jun 2, 2022 06:59AM Immatics (IMTX) and Bristol Myers Squibb (BMY) Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 2, 2022 06:59AM Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 2, 2022 06:59AM Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Jun 1, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
Jun 1, 2022 06:59AM Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
May 28, 2022 07:38AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Two Opdivo-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 27, 2022 06:11PM U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 26, 2022 05:01PM Bristol-Myers Squibb (BMY) Reports Phase 2 PILOT Study Data of CAR T cell Therapy Breyanzi Shows Substantial Durable Responses
May 26, 2022 05:00PM Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line
May 26, 2022 06:59AM Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference
May 19, 2022 06:59AM Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
May 16, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports CheckMate -901 Trial Did Not Meet Enpoints
May 16, 2022 06:59AM Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carc
May 13, 2022 07:00AM Bristol-Myers Squibb (BMY) Sells Manufacturing Facility in East Syracuse, New York to LOTTE
May 13, 2022 06:59AM LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York
View More Recent Stories View Older Stories